Capital Advisors Inc. OK acquired a new stake in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 50,000 shares of the company's stock, valued at approximately $292,000. Capital Advisors Inc. OK owned about 0.07% of Mind Medicine (MindMed) as of its most recent filing with the SEC.
A number of other hedge funds have also recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC raised its stake in shares of Mind Medicine (MindMed) by 32.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,550 shares of the company's stock worth $94,000 after buying an additional 3,350 shares during the period. Deutsche Bank AG lifted its stake in Mind Medicine (MindMed) by 52.7% in the 4th quarter. Deutsche Bank AG now owns 71,595 shares of the company's stock valued at $498,000 after buying an additional 24,716 shares in the last quarter. Tang Capital Management LLC acquired a new stake in Mind Medicine (MindMed) in the 4th quarter worth about $1,392,000. Wells Fargo & Company MN increased its stake in Mind Medicine (MindMed) by 61.8% during the 4th quarter. Wells Fargo & Company MN now owns 39,974 shares of the company's stock worth $278,000 after buying an additional 15,269 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Mind Medicine (MindMed) by 20.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 85,044 shares of the company's stock valued at $592,000 after acquiring an additional 14,691 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently commented on MNMD shares. Cantor Fitzgerald upgraded Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Tuesday, May 13th. Chardan Capital reaffirmed a "buy" rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, May 9th. Eight equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Mind Medicine (MindMed) has an average rating of "Buy" and a consensus target price of $25.50.
Read Our Latest Research Report on MNMD
Insider Buying and Selling at Mind Medicine (MindMed)
In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 7,848 shares of Mind Medicine (MindMed) stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total transaction of $53,366.40. Following the completion of the sale, the insider directly owned 438,329 shares in the company, valued at $2,980,637.20. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert Barrow sold 26,491 shares of the company's stock in a transaction on Wednesday, June 25th. The stock was sold at an average price of $6.80, for a total value of $180,138.80. Following the sale, the chief executive officer directly owned 830,065 shares in the company, valued at $5,644,442. This represents a 3.09% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,830 shares of company stock valued at $311,644 over the last 90 days. 2.45% of the stock is owned by insiders.
Mind Medicine (MindMed) Stock Performance
Shares of NASDAQ MNMD traded up $0.25 during midday trading on Wednesday, reaching $7.72. 1,231,874 shares of the stock were exchanged, compared to its average volume of 1,327,595. The company has a quick ratio of 7.27, a current ratio of 7.27 and a debt-to-equity ratio of 0.10. The company has a 50 day simple moving average of $7.01 and a 200 day simple moving average of $6.89. Mind Medicine has a twelve month low of $4.70 and a twelve month high of $10.44.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, sell-side analysts forecast that Mind Medicine will post -1.35 earnings per share for the current fiscal year.
Mind Medicine (MindMed) Company Profile
(
Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Further Reading
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
